Literature DB >> 2170446

Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.

B J Owens1, G M Anantharamaiah, J B Kahlon, R V Srinivas, R W Compans, J P Segrest.   

Abstract

The envelope (membrane) glycoprotein of HIV is essential for virus attachment and entry into host cells. Additionally, when expressed on the plasma membrane of infected cells, the envelope protein is responsible for mediating cell-cell fusion which leads to the formation of multinucleated giant cells, one of the major cytopathic effects of HIV infections. The envelope glycoproteins of HIV contain regions that can fold into amphipathic alpha-helixes, and these regions have been suggested to play a role in subunit associations and in virus-induced cell fusion and cytopathic effects of HIV. We therefore tested the possibility that amphipathic helix-containing peptides and proteins may interfere with the HIV amphipathic peptides and inhibit those steps of HIV infection involving membrane fusion. Apolipoprotein A-I, the major protein component of high density lipoprotein, and its amphipathic peptide analogue were found to inhibit cell fusion, both in HIV-1-infected T cells and in recombinant vaccinia-virus-infected CD4+ HeLa cells expressing HIV envelope protein on their surfaces. The amphipathic peptides inhibited the infectivity of HIV-1. The inhibitory effects were manifest when the virus, but not cells, was pretreated with the peptides. Also, a reduction in HIV-induced cell killing was observed when virus-infected cell cultures were maintained in presence of amphipathic peptides. These results have potential implications for HIV biology and therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170446      PMCID: PMC296843          DOI: 10.1172/JCI114819

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  The effect of a carbobenzoxy tripeptide on the biological activities of measles virus.

Authors:  E Norrby
Journal:  Virology       Date:  1971-06       Impact factor: 3.616

Review 2.  Membrane fusion proteins of enveloped animal viruses.

Authors:  J White; M Kielian; A Helenius
Journal:  Q Rev Biophys       Date:  1983-05       Impact factor: 5.318

Review 3.  Apolipoprotein/lipid interactions: studies with synthetic polypeptides.

Authors:  J T Sparrow; A M Gotto
Journal:  CRC Crit Rev Biochem       Date:  1982

4.  Sequence and structural homologies among type I and type II interferons.

Authors:  W F DeGrado; Z R Wasserman; V Chowdhry
Journal:  Nature       Date:  1982-11-25       Impact factor: 49.962

5.  Studies of synthetic peptide analogs of the amphipathic helix. Effect of charged amino acid residue topography on lipid affinity.

Authors:  P Kanellis; A Y Romans; B J Johnson; H Kercret; R Chiovetti; T M Allen; J P Segrest
Journal:  J Biol Chem       Date:  1980-12-10       Impact factor: 5.157

6.  Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides.

Authors:  C D Richardson; A Scheid; P W Choppin
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

7.  Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs.

Authors:  R V Srinivas; B Birkedal; R J Owens; G M Anantharamaiah; J P Segrest; R W Compans
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

8.  Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine.

Authors:  G M Anantharamaiah; J L Jones; C G Brouillette; C F Schmidt; B H Chung; T A Hughes; A S Bhown; J P Segrest
Journal:  J Biol Chem       Date:  1985-08-25       Impact factor: 5.157

9.  Oligopeptides that specifically inhibit membrane fusion by paramyxoviruses: studies on the site of action.

Authors:  C D Richardson; P W Choppin
Journal:  Virology       Date:  1983-12       Impact factor: 3.616

10.  Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia.

Authors:  C J Glueck; P Gartside; R W Fallat; J Sielski; P M Steiner
Journal:  J Lab Clin Med       Date:  1976-12
View more
  21 in total

1.  Structural and immunochemical correspondence between HIV-1 and apolipoprotein A-1 envelope proteins.

Authors:  L E Panin; N E Kostina; O N Poteryaeva; V A Lukashev
Journal:  Dokl Biochem Biophys       Date:  2001 Mar-Apr       Impact factor: 0.788

2.  The role of structural and functional homology between human apolipoprotein A-I and envelope proteins of human immunodeficiency virus type 1 in CD4 receptor binding.

Authors:  L E Panin; N E Kostina; V A Lukashev
Journal:  Dokl Biochem Biophys       Date:  2002 Jul-Aug       Impact factor: 0.788

Review 3.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Antimicrobial activity of lipoprotein particles containing apolipoprotein Al.

Authors:  N Tada; T Sakamoto; A Kagami; K Mochizuki; K Kurosaka
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

5.  Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol.

Authors:  A J Mendez; G M Anantharamaiah; J P Segrest; J F Oram
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 6.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

7.  Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression.

Authors:  Trevor D Burt; Brian K Agan; Vincent C Marconi; Weijing He; Hemant Kulkarni; Jeffrey E Mold; Marielle Cavrois; Yadong Huang; Robert W Mahley; Matthew J Dolan; Joseph M McCune; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

8.  Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activity.

Authors:  Bridie A Kelly; Ian Harrison; Aine McKnight; Curtis B Dobson
Journal:  BMC Immunol       Date:  2010-03-18       Impact factor: 3.615

9.  Proteomic analysis of purified coronavirus infectious bronchitis virus particles.

Authors:  Qingming Kong; Chunyi Xue; Xiangpeng Ren; Chengwen Zhang; Linlin Li; Dingming Shu; Yingzuo Bi; Yongchang Cao
Journal:  Proteome Sci       Date:  2010-06-09       Impact factor: 2.480

Review 10.  Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review.

Authors:  Inga Kuhlmann; Anne Marie Minihane; Patricia Huebbe; Almut Nebel; Gerald Rimbach
Journal:  Lipids Health Dis       Date:  2010-01-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.